Several antiangiogenic agents that neutralize or block VEGFR have been approved for treating some cancer entities, including metastatic renal cell carcinoma (RCC), and have become the mainstay of metastatic RCC therapy [3]. The gene discussed is KDR; the disease is renal cell carcinoma.